Skip to main content
SpringerLink
Log in

AUO-Studie AB34/09

Zweiarmige randomisierte Phase-II-Studie zur Chemotherapie mit Gemcitabin und Cisplatin in Kombination mit dem EGF-Rezeptorantikörper Panitumumap (GemCisP) vs. GemCis in der First-line-Therapie beim fortgeschrittenen bzw. metastasierten Urothelkarzinom bei Patienten mit Wild-type-HRAS – PURO

AUO-study AB34/09

An open-label, randomised, multicentre, phase II study to evaluate the efficacy of chemotherapy with gemcitabine and cisplatin in combination with the EGF receptor antibody panitumumab (GemCisP) versus GemCis in the first-line therapy of locally advanced/metastatic urothelial carcinoma in patients with wild-type HRAS – PURO

  • AUO
  • Published:
Der Urologe Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Author information

Authors and Affiliations

  1. Geschäftsstelle der AUO, MeckEvidence, Seestraße 11, 17252, Schwarz, Deutschland

    H. Rexer

Authors
  1. H. Rexer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Rexer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rexer, H. AUO-Studie AB34/09. Urologe 50, 230–232 (2011). https://doi.org/10.1007/s00120-011-2513-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-011-2513-y

Search

Navigation